Malignancy risk in Australian rheumatoid arthritis patients treated with anti-tumour necrosis factor therapy: an update from the Australian Rheumatology Association Database (ARAD) prospective cohort study

被引：0
|
作者：
Margaret P. Staples
Lyn March
Catherine Hill
Marissa Lassere
Rachelle Buchbinder
机构：
[1] Cabrini Institute,Monash Department of Clinical Epidemiology
[2] Monash University,Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine
[3] Royal North Shore Hospital,Florance and Cope Professorial Department of Rheumatology
[4] Institute of Bone and Joint Research,Discipline of Medicine
[5] University of Sydney,undefined
[6] The Queen Elizabeth and Royal Adelaide Hospitals,undefined
[7] University of Adelaide,undefined
[8] St George Hospital,undefined
[9] University of New South Wales,undefined
来源：
BMC Rheumatology | / 3卷
关键词：
Rheumatoid arthritis; Malignancy; Tumour necrosis factor; Biologic therapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 44 条
  • [21] Risk of malignancy in patients with rheumatoid arthritis after anti-tumor necrosis factor therapy: results from Korean National Health Insurance claims data
    Jung, Seung Min
    Kwok, Seung-Ki
    Ju, Ji Hyeon
    Park, Yong-Boom
    Park, Sung-Hwan
    KOREAN JOURNAL OF INTERNAL MEDICINE, 2019, 34 (03) : 669 - 677
  • [22] Impact of inadequate adherence on response to subcutaneously administered anti-tumour necrosis factor drugs: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort
    Bluett, James
    Morgan, Catharine
    Thurston, Layla
    Plant, Darren
    Hyrich, Kimme L.
    Morgan, Ann W.
    Wilson, Anthony G.
    Isaacs, John D.
    Cordingley, Lis
    Barton, Anne
    RHEUMATOLOGY, 2015, 54 (03) : 494 - 499
  • [23] A Prospective Study to Monitor for Tuberculosis During Anti-tumour Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease and Immune-mediated Inflammatory Diseases
    Lee, Choon Kin
    Wong, Sunny H. V.
    Lui, Grace
    Tang, Whitney
    Tam, Lai San
    Ip, Margaret
    Hung, Esther
    Chen, Minhu
    Wu, Justin C.
    Ng, Siew C.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 (08) : 954 - 962
  • [24] Six-Month Follow-Up of Periodontal Condition in Rheumatoid Arthritis and Ankylosing Spondylitis Arthritis Patients Undergoing Anti-Tumour Necrosis Factor-α Therapy
    Tar, Ildiko
    Vegh, Edit
    Martos, Renata
    Soos, Boglarka
    Marton, Ildiko
    Szekanecz, Zoltan
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (02)
  • [25] Long-term anti-tumour necrosis factor therapy reverses the progression of carotid intima–media thickness in female patients with active rheumatoid arthritis
    A. Ferrante
    A. R. Giardina
    F. Ciccia
    G. Parrinello
    G. Licata
    G. Avellone
    E. Giardina
    R. Impastato
    Giovanni Triolo
    Rheumatology International, 2009, 30 : 193 - 198
  • [26] Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-alpha (cA2) therapy
    Brennan, FM
    Browne, KA
    Green, PA
    Jaspar, JM
    Maini, RN
    Feldmann, M
    BRITISH JOURNAL OF RHEUMATOLOGY, 1997, 36 (06): : 643 - 650
  • [27] Association of Tumor Necrosis Factor Inhibitors with the Risk of Nontuberculous Mycobacterial Infection in Patients with Rheumatoid Arthritis: A Nationwide Cohort Study
    Park, Hyun Jin
    Choi, Boyoon
    Song, Yun-Kyoung
    Oh, Yoon-Jeong
    Lee, Eun Bong
    Kim, In-Wha
    Oh, Jung Mi
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (22)
  • [28] Long-term anti-tumour necrosis factor therapy reverses the progression of carotid intima-media thickness in female patients with active rheumatoid arthritis
    Ferrante, A.
    Giardina, A. R.
    Ciccia, F.
    Parrinello, G.
    Licata, G.
    Avellone, G.
    Giardina, E.
    Impastato, R.
    Triolo, Giovanni
    RHEUMATOLOGY INTERNATIONAL, 2009, 30 (02) : 193 - 198
  • [29] Changes in disease characteristics and response rates among patients in the United Kingdom starting anti-tumour necrosis factor therapy for rheumatoid arthritis between 2001 and 2008
    Hyrich, Kimme L.
    Watson, Kath D.
    Lunt, Mark
    Symmons, Deborah P. M.
    RHEUMATOLOGY, 2011, 50 (01) : 117 - 123
  • [30] Effectiveness and safety of anti-tumour necrosis factor therapy with certolizumab pegol observed in real-life rheumatoid arthritis patients in Germany: results from the non-interventional FαsT study
    Burmester, G.
    Nuesslein, H.
    von Hinueber, U.
    Detert, J.
    Richter, C.
    Kumke, T.
    Leunikava, I.
    Lendl, U.
    Fricke, D.
    Mueller-Ladner, U.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2019, 37 (05) : 842 - 851
12345